US judge allows suit challenging Myriad patents on breast cancer genes to proceed
This article was originally published in RAJ Devices
Executive Summary
A US federal judge has ruled that a lawsuit can move forward against the US Patent and Trademark Office (PTO) and Myriad Genetics, which licensed patents covering the BRCA1 and BRCA2 genes known to help detect an increased risk of breast cancer and ovarian cancer1.